Long-Term Efficacy and Safety of Repeated Rituximab to Maintain Remission in Idiopathic Childhood Nephrotic Syndrome: An International Study.
Eugene Yu Hin ChanEllen Lok Man YuAndrea AngelettiZainab ArslanBiswanath BasuOlivia BoyerChang Yien ChanManuela ColucciGuillaume DorvalClaire DossierStefania DrovandiGian Marco GhiggeriDebbie S GipsonRiku HamadaJulien HoganKenji IshikuraKoichi KameiMarkus J KemperAlison Lap-Tak MaRulan S ParekhSeetha RadhakrishnanPriya SainiQian ShenRajiv SinhaChantida SubunSharon TeoMarina VivarelliHazel WebbHong XuHui Kim YapKjell TullusPublished in: Journal of the American Society of Nephrology : JASN (2022)
Children receiving repeated courses of rituximab for FRSDNS experience an improving clinical response. Side effects appear acceptable, but significant complications can occur. These findings support repeated rituximab use in FRSDNS.